中药联合同期放化疗治疗非小细胞肺癌临床研究

Clinical Observation of Chinese Medicine Combined with Concurrent Chemoradiotherapy for Non-small Cell Lung Cancer

目的:探讨中药联合同期放化疗治疗非小细胞肺癌的临床疗效和安全性。方法:将166例非小细胞肺癌患者随机分为对照组和治疗组,各83例。对照组给予TP方案化疗和X线射线放疗,治疗组在对照组的基础上给予艾迪注射液,比较两组临床疗效、卡氏(karnofskym,KPS)评分、生活质量(quality of life,QOL)评分及不良反应的发生情况。结果:治疗组治疗后的KPS和QOL评分显著高于对照组(P<0.05);治疗组的有效率为86.8%,高于对照组的71.1%,且治疗组不良反应发生率低于对照组,差异均具有统计学意义(P<0.05)。结论:艾迪注射液联合同期放化疗治疗非小细胞肺癌的临床疗效显著,可降低放化疗引起的不良反应。

Objective： To explore the clinical effects and safety of Chinese medicine combined with concurrent chemoradiotherapy for nonsmall cell lung cancer. Methods： The 166 patients with NSCLC were divided into control group and therapy group randomly. The patients of control group were given concurrent chemoradiotherapy including chemotherapy with paclitaxel and cisplatin and radiotherapy with Xray. On the basis of the control group,the patients of therapy group were given Chinese medicine Aidi injection. The clinical effects,KPS and QOL scores and adverse effects were observed and compared. Results： After therapy,the total effective rate of the therapy group was significantly higher than that of control group（ P〈0. 05）. The scores of KPS and QOL of therapy group were significantly higher than that of control group（ P〈0. 05）. The effective rate of therapy group was 86. 8%,and which were higher than that of control group71. 1%. The incidence rate of adverse effects of the therapy group was lower than that of the control group instead（ P〈0. 05）. Conclusion： Chinese medicine combined with concurrent chemoradiotherapy has better clinical effect as well as relieve the toxic side effects.